摘要
门冬胰岛素是临床广泛应用的速效胰岛素类似物,适用于成人、青少年和儿童糖尿病患者以及妊娠期糖尿病患者,具有良好的安全性、有效性、经济性和患者依从性,给患者带来多重获益。本文结合2021版《2型糖尿病短期胰岛素强化治疗专家共识》的更新亮点,重点总结门冬胰岛素(诺和锐®)在强化治疗临床实践的证据和应用策略,从而为短期胰岛素强化治疗在各级医疗机构的规范使用提供新的参考。
Insulin aspart is the rapid-acting insulin analog extensively used by patients in clinical settings.It is suitable for adults,adolescents and children with diabetes,as well as patients with gestational diabetes.It has brought many benefits to patients,and has good safety,efficacy,economical efficiency and patient compliance.Based on the updated highlights of the"Expert Consensus on Short-term Intensive Insulin Therapy for Type 2 Diabetes(2021 Edition)",this article focuses on summarizing the evidence and application strategies of insulin aspart in intensive treatment clinical practice,and provides a standard for shortterm intensive insulin therapy in clinical institutions at all levels application for reference.
作者
李玉秀
LI Yuxiu(Chinese Academy of Medical Sciences,Peking Union Medical College,Department of Endocrinology Pecking Union Medical College Hospital and Key Laboratory of National Health Commission,Beijing 100730,China)
出处
《药品评价》
CAS
2023年第4期391-394,共4页
Drug Evaluation
关键词
糖尿病
门冬胰岛素
短期胰岛素强化治疗
Diabetes mellitus
Insulin aspart
Short-term intensive insulin therapy
